CN1207941A - Anti-senility medicine and its preparation - Google Patents
Anti-senility medicine and its preparation Download PDFInfo
- Publication number
- CN1207941A CN1207941A CN98117329A CN98117329A CN1207941A CN 1207941 A CN1207941 A CN 1207941A CN 98117329 A CN98117329 A CN 98117329A CN 98117329 A CN98117329 A CN 98117329A CN 1207941 A CN1207941 A CN 1207941A
- Authority
- CN
- China
- Prior art keywords
- radix
- fructus
- jin
- rhizoma
- antiaging agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The anti-senility medicine is prepared with 30-odd Chinese medicinal materials including Radix Polygoni Multiflori, tuckahoe, pilose antler, Radix asparagi, Rhizoma Atractylodis, etc. in certain proportion. It can prevent senility, strengthen immunity of organism and improve sleep quality. It has obvious remission effect to senility symptoms, such as dizziness, aching back and legs, fatigue, insomnia amnesia, etc. The present invention also discloses the preparation process of the said medicine.
Description
The present invention relates to a kind of antiaging agent and preparation method thereof.
In existing defying age medicine, though the external Western medicine that adopts has certain effect, but general equal toxic side effect, and only cure the symptoms, not the disease, plurality kinds of health care product such as ginseng royal jelly are arranged in the Chinese medicine at home, its drug effect is also not ideal enough, act on single, not obvious to disease effects such as body's immunological function, neurasthenia, sexual impotence, seminal emission, sexual hypofunctions.
The purpose of this invention is to provide a kind of preventing aging, enhancing human body immunity function and the length of one's sleep, to the antiaging agent of having a dizzy spell, syndrome of deficiency of kidney-YANG such as soreness of the waist and knees, spiritlessness and weakness, insomnia forgetfulness, aversion to cold and cold limbs, impotence, hyposexuality, seminal emission has obvious mitigation.
Another object of the present invention provides a kind of preparation method for preparing antiaging agent.
Antiaging agent is by the medicament of making by weight ratio in the following bulk drugs:
Radix Polygoni Multiflori 1000 Poria 200 Cornu Cervi Pantotrichums 3 Radix Asparagi 200
Rhizoma Atractylodis 200 Olibanums 200 Rhizoma Dioscoreaes 200 Canis familiaris L. Fructus Lyciis 300
Herba Leonuri 300 Fructus Alpiniae Oxyphyllae 200 Rhizoma Cibotii 200 Cortex Lycii 200
Radix Rehmanniae Preparata 200 Radixs Astragali 300 Radix Salviae Miltiorrhizaes 250 pollen 50
Radix Angelicae Sinensis 200 Radix Et Rhizoma Rhei, 150 Herb Gynostemmae Pentaphyllis 400,300 Radix Ophiopogonis
Rhizoma Curcumae 250 Semen Plantaginiss 50 Semen Coiciss 200 Fructus Jujubaes 250
Herba Taxilli 200 Radix Curcumaes 200 Herba Artemisiae Scopariaes 300 Fructus Schisandrae Chinensis 250
Fructus Psoraleae 250 field dobbers 200 Flos Carthamis 200 Endothelium Corneum Gigeriae Galli 300
Fructus Hordei Germinatus (parched) 300 Radix Morindae Officinaliss 250 Semen Platycladi 200 celestial buds 200
The preparation method of antiaging agent, be various crude drug to be added to extract in the pot in proportion, add the water of 5 times of its crude drug gross weights and the alcoholic solution of 50% weight, the concentration of ethanol is 60-80%, heats up to decoct, extract the active ingredient in each crude drug, decoct temperature 95-98 degree, decocting time 3.5-4.5 hour, reclaim filtration then, in filtrate, add antiseptic, adjust proportion, pH value with Lac regis apis at last.
Sodium benzoate and sodium citrate that antiseptic adopts, its consumption is respectively 3 ‰ and 5% ‰ of a filtrate total amount.
The proportion of Lac regis apis adjustment is 1.15, pH value 5.6.
Antiaging agent of the present invention can prevent aging, enhancing human body immunity function and the length of one's sleep, to have a dizzy spell, deficiency of kidney-YANG syndrome such as soreness of the waist and knees, spiritlessness and weakness, insomnia forgetfulness, aversion to cold and cold limbs, impotence, hyposexuality, seminal emission has obvious mitigation.
Clinical experiment report data of the present invention is as follows:
The I clinical trial phase
One, physical data
31 routine patients are the male, 3 examples below 30 years old wherein, 31-40 year 7 examples, 41-50 year 10 examples, 51-60 year 10 examples, 1 example more than 61 years old.Age reckling 28 years old, the maximum 68 years old, the mean age is 45 years old, and course of disease person below 3 years is 26 examples among the 31 routine patients, and the person is 5 examples more than 3 years.
Two, observational technique
1, diagnostic criteria: with reference to " the dialectical reference standard of deficiency syndrome " execution of Zhengzhou in 1986 whole nation combination of Chinese and Western medicine deficiency syndrome and senile disease research academic conference revision.
2, case is selected: allly meeting the insufficiency of kidney-YANG diagnostic criteria, is that the debate such as sexual hypofunction, seminal emission, sexual impotence and the inpatient of main clinical manifestation all can be used as the clinical observation object with dizziness and tinnitus, soreness of the waist and knees, aversion to cold and cold limbs, spiritlessness and weakness, insomnia forgetfulness etc.
3, observation medicine: antiaging agent of the present invention.
4, research method: all MethodsThe cases enrolled are all filled in symptom, sign and auxiliary examination project by the requirement of observation table.Its symptom by light (+), in (++), heavy (+++) fill in.Take medicine every day 3 times, each 20ml, 30 days is a course of treatment.Inactive other strengthening by means of tonics medicine during the treatment finishes the back comprehensive review course of treatment, adopts treatment front and back self-controlled method, and its result carries out statistical procedures with rank test and t check.
Three, observed result
1, curative effect determinate standard:
Produce effects: cardinal symptom by +++→+; +++, ++ →-.
Effectively: +++→; ++ →+is invalid, the symptom no change.
2, to the influence of symptoms such as dizziness and tinnitus
Table 1 antiaging agent of the present invention is to the influence of symptoms such as dizziness and tinnitus
Control back symptom U P before controlling
++++++-++++++-dizziness and tinnitus 1 17 13 0001 30 3.39＜0.01 soreness and weakness of waist and knees 13 17 10002 29 3.34＜0.01 spiritlessness and weakness 1 19 11 0000 31 3.83＜0.01 insomnia forgetfulness 0 15 16 0007 24 4.09＜0.01 aversion to cold and cold limbs 13 14 14 0016 24 3.6＜0.01 impotence 17 14 00154 21 3.06＜0.01 sexual hypoesthesia 16 15 00064 21 3.63＜0.01 seminal emission 9 21 10039 19 3.77＜0.01
By table 1 as seen, there is significant differences in this product symptom effects such as dizziness and tinnitus that have clear improvement before and after the treatment.
3, to the influence of 24h urine, 17 hydroxyls, margarone
Table 2 antiaging agent of the present invention is to the influence of 24h urine, 17 hydroxyls, margarone
Control back t p 17 hydroxyls 7.67 ± 1.69 12.37 ± 2.92 9.21＜0.01 margarones 10.93 ± 2.75 17.18 ± 2.97 10.97＜0.01 before controlling
Be significantly increased twenty-four-hour urine 17 hydroxyls 17 ketolysises by the visible this product of table 2, have significant differences before and after the treatment, illustrate that this product has the effect of the deficiency of kidney-YANG syndrome of improvement.
4, to the influence of body's immunity
Table 3 antiaging agent of the present invention is to the influence of body's immunity (X ± SD)
Control rear n t pIgA 0.91 ± 0.65 3.26 ± 0.23 31 19.35＜0.001jgc 3.16 ± 1.93 14.3 ± 2.54 31 11.28＜0.001IgM 0.50 ± 0.24 1.68 ± 0.31 31 19.38＜0.001C3 0.82 ± 0.14 1.43 ± 0.07 31 19.44＜0.001 pouring before controlling and turn to 30.87 ± 9.11 59.74 ± 2.01 31 19.62＜0.001
By the visible this product of table 3 effect of obvious enhancing human body immunity function is arranged, have significant difference before and after the treatment.
5, to the influence of the length of one's sleep, grip
Table 4 antiaging agent of the present invention is to the influence of the length of one's sleep, grip (X ± SD)
Control back n t p grip 25.84 lengths of one's sleep 4.94 ± 0.57 7.94 ± 0.25 31 32.35＜0.001 ± 1.51 26.84 ± 1.34 31 8.15＜0.001 before controlling
By table 4 as seen, antiaging agent of the present invention is significantly increased the effect of the length of one's sleep and human body grip, has significant difference before and after the treatment.
6, to the influence of blood RBC and Hb
Before controlling, n controls (X10 °/L) 31 3.81 ± 0.55 4.58 ± 0.53 10.31＜0.01Hb (g/L) 31 108.71 ± 16.28 147.74 ± 15.64 17.9＜0.01 of back t pRBC
By table 5 as seen, this product is significantly increased the effect of body RBC and Hb, has significant difference before and after the treatment.
7, other
31 routine patient's clinical observation result show that this product does not have side effect such as obvious hepatic and renal function damage.
8, comprehensive therapeutic effect
This is organized among the 31 routine patients, and produce effects 20 examples are 64.5%, and effective 10 examples are 32.3%, and invalid 1 example is 3.2%, and total effective rate is 96.8%.
Discuss
Antiaging agent clinical effectiveness of the present invention shows that this product when symptom is suffered from a deficiency of the kidney in improvement, is significantly increased the length of one's sleep, and the enhancing human body immunity function increases the effect of 17 hydroxyls, 17 ketone content and body grip.Can be used for sexual inadequacy, sexual impotence, seminal emission, etc. sick prevention and treatment.
In a word, this medicine is a kind of curative effect health-care good product preferably, and the clinical observation total effective rate is 96.8%, and the value of further applying is arranged.
The II clinical trial phase
One, physical data
1, sex and age
Male's 109 examples among the 115 routine patients, women's 6 examples; Age 20-29 year 10 examples, 30-39 year 27 examples, 40-49 year person's 34 examples, 50-59 year person's 23 examples, person's 21 examples more than 60 years old, age minimum are 20 years old, the maximum is 73 years old.
2, course of disease data
(1) case is selected
All dizziness and tinnitus, soreness of the waist and knees, spiritlessness and weakness, insomnia forgetfulness, aversion to cold and cold limbs etc. are with deficiency of kidney-essence, order fiery void decline for sexual impotence, seminal emission, the sexual hypofunction person of main performance all applicable.
(2) observational technique
Fill in symptom by the observation plan requirement before the medication, sign and auxiliary examination project, oral three times of every day, each 10ml, one month is a course of treatment, other relevant strengthening by means of tonics medicine of stopping using during the treatment.
(3) efficacy assessment standard
Produce effects: cardinal symptom disappears, or by +++→, +++,+→-, effectively: cardinal symptom alleviates, or +++→ ++, ++ →+; Invalid: the cardinal symptom no change.
Three, interpretation of result
1, produce effects 85 examples among the total effective rate 115 routine patients are 73.91%; Effective 27 examples are 23.5%, and invalid 3 examples are 2.6%, and total effective rate is 97.4%.
2, to the influence of erythrocyte and hemoglobin
Table 1 antiaging agent of the present invention is to the influence of erythrocyte and hemoglobin
After treating before the treatment
n t p
X ± SD X ± SD erythrocyte 115 4.71 ± 0.80 4.78 ± 0.72 1.90 0.05 hemoglobin 115 138.54 ± 26.04 140.14 ± 25.01 1.10 0.05
By table 1 as seen, this product does not have influence to erythrocyte and hemoglobin.
3, to the cardinal symptom influence such as having a dizzy spell and the soreness of waist is soft
Table 2 antiaging agent of the present invention is to having a dizzy spell and the influence of cardinal symptom such as soreness of the waist and knees
Control back symptom n before controlling
u p
++++++-++++++-dizziness and tinnitus 115 42 53 15 512 43 69 8.59 0.01 soreness and weakness of waist and knees 115 60 40 15 007 48 60 8.72 0.01 spiritlessness and weakness 115 50 43 20 208 48 59 8.73 0.01 insomnia forgetfulness 115 30 43 35 715 34 75 8.84 0.01 aversion to cold and cold limbs 115 16 49 26 14 04 31 80 8.85 0.01 impotences 115 23 48 26 18 04 33 78 8.89 0.01 sexual hypoesthesiies 115 39 36 37 307 36 72 8.81 0.01 seminal emissions 115 8 19 34 54 015 109 9.06 0.01
By table 2 as seen, this product to have a dizzy spell, cardinal symptom such as soreness of the waist and knees has clear improvement, significant difference before and after the treatment, p value is equal＜0.01.
4, other
This product does not have influence to erythrocyte and hemoglobin
Clinical 115 routine observed results show that this product does not have obvious poison and pays effect.
Brief summary
Clinical 115 routine observed results show, antiaging agent of the present invention to have a dizzy spell, syndrome of deficiency of kidney-YANG such as soreness of the waist and knees, spiritlessness and weakness, insomnia forgetfulness, aversion to cold and cold limbs, impotence, hyposexuality, seminal emission has obvious mitigation, but and the enhancing human body immunity function and the length of one's sleep, clinical observation always effectively reaches 97.4%, can be used for sexual inadequacy, sexual impotence, prevention and treatment that seminal emission etc. are sick, be curative effect health-care good product preferably, the value of further applying is arranged.
Embodiments of the invention are as follows:
Get 1000 jin of crude drug Radix Polygoni Multiflori, 200 jin in Poria, 3 jin in Cornu Cervi Pantotrichum, 200 jin of Radix Asparagi, 200 jin of Rhizoma Atractylodis, 200 jin of Olibanums, 200 jin of Rhizoma Dioscoreaes, 300 jin of Canis familiaris L. Fructus Lyciis, 300 jin of Herba Leonuris, 200 jin of Fructus Alpiniae Oxyphyllae, 200 jin of Rhizoma Cibotii, 200 jin of Cortex Lycii, 200 jin in Radix Rehmanniae Preparata, 300 jin of the Radixs Astragali, 250 jin of Radix Salviae Miltiorrhizaes, 50 jin of pollen, 300 jin of Radix Angelicae Sinensis, 200 jin of Radix Ophiopogonis, 150 jin of Radix Et Rhizoma Rhei, 400 jin of Herb Gynostemmae Pentaphyllis, 250 jin of Rhizoma Curcumae, 50 jin of Semen Plantaginiss, 200 jin of Semen Coiciss, 250 jin of Fructus Jujubaes, 200 jin of Herba Taxillis, 200 jin of Radix Curcumaes, 300 jin of Herba Artemisiae Scopariaes, 250 jin of Fructus Schisandrae Chinensis, 250 jin of Fructus Psoraleaes, 200 jin of field dobbers, 200 jin on Flos Carthami, 300 jin of Endothelium Corneum Gigeriae Galli, 300 jin of Fructus Hordei Germinatus (parched)s, 250 jin of Radix Morindae Officinaliss, 200 jin of Semen Platycladi, celestial bud all adds in the extraction pot for 200 jin, the alcoholic solution that adds 43265 jin of water and 4326.5 jin, alcohol concentration is 60%, the decoction of heating, extract the active ingredient in each crude drug, decoct temperature 95 degree, decocting time 4 hours, reclaim filtration then, add preservative sodium benzoate and sodium citrate in filtrate, its consumption is respectively 3 ‰ and 5 ‰ of a filtrate total amount.Adjusting proportion with Lac regis apis at last is 1.15, and pH value is 5.6.
Claims (4)
1, a kind of antiaging agent is characterized in that the medicament of being made by weight ratio by following bulk drugs:
Radix Polygoni Multiflori 1000 Poria 200 Cornu Cervi Pantotrichums 3 Radix Asparagi 200
Rhizoma Atractylodis 200 Olibanums 200 Rhizoma Dioscoreaes 200 Canis familiaris L. Fructus Lyciis 300
Herba Leonuri 300 Fructus Alpiniae Oxyphyllae 200 Rhizoma Cibotii 200 Cortex Lycii 200
Radix Rehmanniae Preparata 200 Radixs Astragali 300 Radix Salviae Miltiorrhizaes 250 pollen 50
Radix Angelicae Sinensis 200 Radix Et Rhizoma Rhei, 150 Herb Gynostemmae Pentaphyllis 400,300 Radix Ophiopogonis
Rhizoma Curcumae 250 Semen Plantaginiss 50 Semen Coiciss 200 Fructus Jujubaes 250
Herba Taxilli 200 Radix Curcumaes 200 Herba Artemisiae Scopariaes 300 Fructus Schisandrae Chinensis 250
Fructus Psoraleae 250 field dobbers 200 Flos Carthamis 200 Endothelium Corneum Gigeriae Galli 300
Fructus Hordei Germinatus (parched) 300 Radix Morindae Officinaliss 250 Semen Platycladi 200 celestial buds 200
2, the method for preparation antiaging agent as claimed in claim 1, it is characterized in that in proportion various crude drug being added extracting in the pot, add the water of 5 times of its crude drug gross weights and the alcoholic solution of 50% weight, the concentration of ethanol is 60-80%, heats up to decoct, extract the active ingredient in each crude drug, decoct temperature 95-98 degree, decocting time 3.5-4.5 hour, reclaim filtration then, in filtrate, add antiseptic, adjust proportion, pH value with Lac regis apis at last.
3, preparation method according to claim 2, what it is characterized in that the antiseptic employing is sodium benzoate and sodium citrate, its consumption is respectively 3 ‰ and 5 ‰ of a filtrate total amount.
4, according to claim 2 or 3 described preparation methoies, the proportion that it is characterized in that the Lac regis apis adjustment is 1.15, and pH value is 5.6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98117329A CN1063083C (en) | 1998-08-17 | 1998-08-17 | Anti-senility medicine and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98117329A CN1063083C (en) | 1998-08-17 | 1998-08-17 | Anti-senility medicine and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1207941A true CN1207941A (en) | 1999-02-17 |
| CN1063083C CN1063083C (en) | 2001-03-14 |
Family
ID=5225475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98117329A Expired - Fee Related CN1063083C (en) | 1998-08-17 | 1998-08-17 | Anti-senility medicine and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1063083C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1084204C (en) * | 1999-04-26 | 2002-05-08 | 刘祖文 | Health-care fleece flower root-pollen food and its preparing process |
| CN101133835B (en) * | 2007-10-10 | 2011-04-20 | 李志民 | Health-care food having functions of improving female immunity and nourishing face |
| CN104473154A (en) * | 2014-11-20 | 2015-04-01 | 青岛恒波仪器有限公司 | Health mulberry oral liquid capable of delaying senescence and preparation method of health mulberry oral liquid |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1066788A (en) * | 1992-07-01 | 1992-12-09 | 王勇 | The method for making of body-strengthening nutrient oral liquid and purposes in the Asia |
| CN1170588A (en) * | 1996-07-16 | 1998-01-21 | 郝来勤 | Pure natural plant human life energy nutritive substrate |
| CN1060960C (en) * | 1997-06-26 | 2001-01-24 | 周淑琴 | Health-care wine with antisenility function |
-
1998
- 1998-08-17 CN CN98117329A patent/CN1063083C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1084204C (en) * | 1999-04-26 | 2002-05-08 | 刘祖文 | Health-care fleece flower root-pollen food and its preparing process |
| CN101133835B (en) * | 2007-10-10 | 2011-04-20 | 李志民 | Health-care food having functions of improving female immunity and nourishing face |
| CN104473154A (en) * | 2014-11-20 | 2015-04-01 | 青岛恒波仪器有限公司 | Health mulberry oral liquid capable of delaying senescence and preparation method of health mulberry oral liquid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1063083C (en) | 2001-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1742939A (en) | Medicine for treating pulmonary fibrosis and preparing method | |
| CN1228066C (en) | Oral liquid for tonifying-kidney and qi contg. eighteen herb medicines, and prepn. method thereof | |
| CN1092981C (en) | Medicine for curing arthralgia-syndrome resulted from wind,cold and dampness and its preparation method | |
| CN1742775A (en) | Medicine composition for preventing and treating orthopedic diseases | |
| CN101810732A (en) | Injury bone growing particle traditional Chinese medicine preparation and production method thereof | |
| CN1063083C (en) | Anti-senility medicine and its preparation | |
| CN101987156B (en) | Medicine for treating toothache and preparation method thereof | |
| CN1318378A (en) | Heat syndrome treating Chinese medicine | |
| CN1169555C (en) | A Chinese medicinal decoction pill for treating hepatitis B | |
| CN1285367C (en) | Medicinal preparation for treating diabetes and its preparation method | |
| CN101979084B (en) | Chinese medicinal composition for warming kidney and tonifying yang and preparation method thereof | |
| CN103301368A (en) | Medicament for treating hyperactivity | |
| CN101912547B (en) | Medicament for treating dizziness and preparation method thereof | |
| CN1253188C (en) | Medicine for treating hypertension and its preparing process | |
| CN1257739C (en) | Senshitong mixture for treating nephrolithiasis | |
| CN1666763A (en) | Dripping pills of six Ingredients with Rehmanniae | |
| CN114617924B (en) | Composition for treating type 2 diabetes | |
| CN101912584A (en) | Medicine for treating melancholia and preparation method thereof | |
| CN1186036C (en) | Diabetes treating medicine and its prepn | |
| CN1739749A (en) | Leukemia treating Chinese medicine composition and its prepn | |
| CN1281265C (en) | Diuretic and menstruation-regulating medicine and its prepn | |
| CN100341543C (en) | Kidney-tonifying brain-invigorating medicine and preparation process thereof | |
| CN103920066A (en) | Method for preparing medicament for treating acute gouty arthritis | |
| CN1182865C (en) | Medicine for treating discomforts in insteines and stomach | |
| CN1376502A (en) | Chinese medicine for treating rheumatism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |